Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11219700 | 1.00 | CA2 (0.44) | CA2MEN1KMT2ATSHRCYP3A4 | |
| SCHEMBL398 | 1.00 | — | — | |
| SCHEMBL10835191 | 1.00 | CA2 (0.44) | CA2MEN1KMT2ATSHRCYP3A4 | |
| SCHEMBL125676 | 1.00 | CA2 (0.44) | CA2MEN1KMT2ATSHRCYP3A4 | |
| SCHEMBL299301 | 1.00 | CA2 (0.44) | CA2MEN1KMT2ATSHRCYP3A4 | |
| SCHEMBL23647292 | 1.00 | CA2 (0.44) | CA2MEN1KMT2ATSHRCYP3A4 | |
| SCHEMBL16546847 | 1.00 | CA2 (0.44) | CA2MEN1KMT2ATSHRCYP3A4 | |
| SCHEMBL5668460 | 1.00 | CA2 (0.44) | CA2MEN1KMT2ATSHRCYP3A4 | |
| SCHEMBL125032 | 1.00 | CA2 (0.44) | CA2MEN1KMT2ATSHRCYP3A4 | |
| SCHEMBL12883094 | 1.00 | CA2 (0.44) | CA2MEN1KMT2ATSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874982-A1 | METHOD FOR ELECTRODEPOSITION OF BRONZES | Enthone, Inc. (US) | 2008-01-09 | — | — | EP | claimed |
| WO-2006113473-A1 | METHOD FOR ELECTRODEPOSITION OF BRONZES | ENTHONE INC. (US) | 2006-10-26 | — | — | WO | claimed |
| US-20110172147-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | CONDE-KNAPE KARIN | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172147-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | NPY2R, NPY1R, NPY4R | CA2 1505/4885MEN1 2145/4885KMT2A 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.